Clinical Trials Logo

Lymphoma, B-cell clinical trials

View clinical trials related to Lymphoma, B-cell.

Filter by:

NCT ID: NCT03383406 Enrolling by invitation - Clinical trials for Diffuse Large B Cell Lymphoma

A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma

IVAM
Start date: December 1, 2016
Phase: Phase 2
Study type: Interventional

A phase II trial of ifosfamide, etoposide, cytarabine, and methotrexate (IVAM) chemotherapy for refractory or relapsed diffuse large B cell lymphoma

NCT ID: NCT03379493 Terminated - Clinical trials for Lymphomas Non-Hodgkin's B-Cell

Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

Start date: April 4, 2018
Phase: Phase 1
Study type: Interventional

This is a non-randomized, single arm, open-label, single institution, phase I study to determine the maximum tolerated dose (MTD) of ET190L1 ARTEMIS™ T cells in patients ≥ 18 years of age with relapsed or refractory CD19+ Non-Hodgkin's lymphoma.

NCT ID: NCT03378947 Completed - Clinical trials for To Characterize and Compare Clinical, Pathological and Molecular Features

EBV-associated Diffuse Large B Cell Lymphoma

Start date: June 1, 2017
Phase:
Study type: Observational

The aim of this study is to characterize and compare clinical, pathological (histology, immunophenotype) and molecular features of EBV-related GZL and DLBCL: do they belong to the same entity or to two different subtypes of EBV-related lymphoma ?

NCT ID: NCT03376958 Completed - Clinical trials for Diffuse Large B Cell Lymphoma

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Start date: January 1, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Apatinib for patients with Relapsed Refractory Diffuse Large B Cell Lymphoma.

NCT ID: NCT03375619 Recruiting - Multiple Myeloma Clinical Trials

Long-term Follow-up Study of Patients Receiving CAR-T Cells

Start date: December 1, 2017
Phase:
Study type: Observational

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)

NCT ID: NCT03373019 Recruiting - Neoplasms Clinical Trials

Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Start date: December 21, 2017
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate therapeutic efficacy of Chidamide combined with R-GDP (rituximab/gemcitabine/dexamethasone/cisplatin)in treating Patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) not suitable for transplantation.

NCT ID: NCT03372837 Completed - Clinical trials for Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Start date: January 15, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with recurrent/relapsed diffuse large B-cell lymphoma.

NCT ID: NCT03367143 Active, not recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma Refractory

Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL

Start date: December 2016
Phase: Phase 2
Study type: Interventional

This study is to evaluate the efficacy and safety of Lenalidomide plus ICE in the treatment of Refractory and Relapsed DLBCL patients.

NCT ID: NCT03366350 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies

Start date: April 15, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This is the second stage of the previous anti-CD19 CAR-T therapy (NCT02965092). The study aims to evaluate the safety and efficacy of consolidative allo-HSCT following CAR-T therapy in patients with relapsed or refractory B cell Malignancies.

NCT ID: NCT03366324 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies

Start date: May 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

For micro residual disease (MRD) positive patients who have undergone at least 2 cycles chemotherapies for their CD19+ B-cell malignancies, there would be much more risks for them to receive hematological stem cell transplantation (HSCT) than MRD- patients. In order to reduce HSCT-related adverse events for these kind of patients, investigators plan to conduct CAR-T therapies on them first to make them achieve MRD- statuses, and then transfer them to HSCT.